Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

49.21 -0.31 (-0.63%)
Streaming Delayed Price Updated: 11:20 AM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) - An Undervalued Stock With Strong Fundamentals ↗
SUPERNUS PHARMACEUTICALS (NASDAQ:SUPN) is an undervalued stock with strong profitability, no debt, and steady growth—making it a potential pick for value investors. 
Via Chartmill
News headline image
1 Stock Under $50 with Exciting Potential and 2 to Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen. 
Via Stocktwits
News headline image
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics ↗
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash. 
Via Stocktwits
Topics Government
News headline image
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio. 
Via Benzinga
News headline image
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space. 
Via Investor's Business Daily
Topics ETFs
News headline image
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
From Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Stocks Facing Headwinds
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 to Keep Off Your Radar
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Cash-Heavy Stocks in the Doghouse
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Dawdling Stocks with Mounting Challenges
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
3 Stocks Under $50 That Concern Us
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the... 
Via StockStory
Topics Earnings
News headline image
Supernus Announces First Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
3 Healthcare Stocks with Mounting Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
Uncover the potential of SUPERNUS PHARMACEUTICALS INC, an undervalued stock. NASDAQ:SUPN maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.